Optimal Treatment Duration of Bevacizumab as Front-Line Therapy for Advanced Ovarian Cancer: AGO-OVAR 17 BOOST/GINECO OV118/ENGOT Ov-15 Open-Label Randomized Phase III Trial

Pfisterer, Jacobus; Joly, Florence; Kristensen, Gunnar; Rau, Joern; Mahner, Sven; Pautier, Patricia; El-Balat, Ahmed; Kurtz, Jean-Emmanuel; Canzler, Ulrich; Sehouli, Jalid; Heubner, Martin L.; Hartkopf, Andreas D.; Baumann, Klaus; Hasenburg, Annette; Hanker, Lars C.; Belau, Antje; Schmalfeldt, Barbara; Denschlag, Dominik; Park-Simon, Tjoung-Won; Selle, Frederic; Jackisch, Christian; Burges, Alexander; Lueck, Hans-Joachim; Emons, Guenter; Meier, Werner; Gropp-Meier, Martina; Schroeder, Willibald; de Gregorio, Nikolaus; Hilpert, Felix; Harter, Philipp

Optimal Treatment Duration of Bevacizumab as Front-Line Therapy for Advanced Ovarian Cancer: AGO-OVAR 17 BOOST/GINECO OV118/ENGOT Ov-15 Open-Label Randomized Phase III Trial

Autor(en):

Pfisterer, Jacobus; Joly, Florence; Kristensen, Gunnar; Rau, Joern; Mahner, Sven; Pautier, Patricia; El-Balat, Ahmed; Kurtz, Jean-Emmanuel; Canzler, Ulrich; Sehouli, Jalid; Heubner, Martin L.; Hartkopf, Andreas D.; Baumann, Klaus; Hasenburg, Annette; Hanker, Lars C.; Belau, Antje; Schmalfeldt, Barbara; Denschlag, Dominik; Park-Simon, Tjoung-Won; Selle, Frederic; Jackisch, Christian; Burges, Alexander; Lueck, Hans-Joachim; Emons, Guenter; Meier, Werner; Gropp-Meier, Martina; Schroeder, Willibald; de Gregorio, Nikolaus; Hilpert, Felix; Harter, Philipp

Tübinger Autor(en):

Hartkopf, Andreas

Erschienen in:

Journal of Clinical Oncology (2023), Bd. 41, H. 4, S. 893-902

Verlagsangabe:

Lippincott Williams & Wilkins

Sprache:

Englisch

Referenz zum Volltext:

http://dx.doi.org/10.1200/JCO.22.01010

ISSN:

0732-183X